Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT by unknown
ORIGINAL RESEARCH
Development and Evaluation of a New Technological
Way of Engaging Patients and Enhancing
Understanding of Drug Tolerability in Early Clinical
Development: PROACT
Andrew Hughes . Donal Landers . Hendrik-Tobias Arkenau . Saj Shah .
Richard Stephens . Amrik Mahal . Matthew Simmons . Charlotte Lemech .
Jennifer Royle
Received: December 9, 2015 / Published online: May 11, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: During early clinical testing of a
new medication, it is critical to understand and
characterise patient tolerability. However, in
early clinical studies, it is difficult for patients to
contribute directly to the sponsors’
understanding of a new compound. Patient
reported opinions about clinical tolerability
(PROACT) provides a new, simple and
innovative way in which patients can
collaborate using an application downloaded
to a mobile computer or smartphone.
Methods: PROACT was designed with special
consideration given to patient confidentiality,
patient engagement and data security. A pilot
study was conducted to investigate patient
uptake of PROACT and to characterize clinical
trial information it captured. Patients recruited
to Phase I oncology trials at a UK center were
eligible to participate but were required to have
a tablet computer or smartphone. Patients used
PROACT to upload audio/video messages that
became available instantly to their clinical
team, who were able to reply to the patient
within PROACT. The patient’s message was
also analyzed, personally-identifiable
information removed and anonymized
information then made available to the
sponsor in an analytics module for
decision-making. In parallel, a patient focus
group was engaged to provide feedback on
communication needs during early clinical
trials and the PROACT concept.
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Results: Of the 16 patients informed of
PROACT, 8 had a smart device and consented
to take part. Use of PROACT varied and all
messages volunteered were relevant and
informative for drug development. Topics
disclosed included tolerability impacts, study
design, and drug formulation. Alignment with
the clinical study data provided a richer
understanding of tolerability and treatment
consequences. This information was available
to be shared among the clinical team and the
sponsor, to improve patient support and
experience. Patient forum feedback endorsed
the concept and provided further information
to enhance the application.
Conclusion: Overall, PROACT achieved proof
of concept in this small pilot study and
delivered a secure end-to-end system that
protected patient privacy and provided
preliminary insight into patient experiences
beyond the usual clinical trial data set. The
use of mobile devices to interact actively with
participants in clinical trials may be a new way
of engaging and empowering patients. Further
validation of this technology in larger patient
cohorts is ongoing.
Funding: AstraZeneca.
Keywords: Oncology; Phase I; Patient
feedback; PROACT; Safety; Tolerability
INTRODUCTION
Pharmaceutical innovation is based on cutting
edge science with the ultimate aim of
improving patients’ lives. However, the path
from innovation through development is
complex and highly regulated [1] with
well-defined but proscriptive technical
requirements for the conduct of clinical trials
[2]. Furthermore, patient outcomes are also
dependent on compliance [3], and those who
do not engage, and therefore, do not comply are
likely to derive lesser benefit. It is no longer
acceptable to rely solely on the scientific output
of the clinical study when the patient’s
experience of the drug and choices made may
be of equal importance, both to the sponsor and
to the patient.
The principal objective in an open-label
Phase I oncology study, is to understand
safety, tolerability and other aspects of the
drug profile, and thus help define a
recommended dose for further investigation
[4]. A major component in determining this is
deciding which dosing regimen is best tolerated
by patients for the duration of study treatment.
This is not easy to address with the clinical
dataset alone, which is entered by the clinical
teams in the clinical trial site, and categorical in
the nature of the data collection, particularly
recording of adverse events. For example, there
may be significant resolution in the severity or
distribution of an event which still remains
within the same severity category, e.g., mild. As
the patients themselves cannot ordinarily share
their experiences directly with a clinical study
sponsor, it is generally the information in the
case report form [5] that is solely relied upon for
drug development decisions. In this case, this
gives the impression of constancy when in fact,
there may have been, to the patient at least, a
significant reduction in the treatment burden
experienced. Incorporating patient-driven
insight, that is shared directly with both the
medical teams and study sponsors, into this
understanding is likely to provide a step-change
in interpretation capability and to result in
more informed decisions [6, 7], particularly for
those adverse events that are not categorized as
being serious.
Laws and regulations governing clinical trials
and data privacy are there to protect patients
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not to stifle innovation and productivity. Yet,
industry, in general, has found it a challenge to
embrace technology within this clinical trial
environment. One of the main concerns among
clinical trial researchers about technology is the
risk that the integrity of the clinical study gets
compromised by introducing technology aimed
at giving some level of control back to the
patient. PROACT (patient reported opinions
about clinical tolerability) is an application
that is designed to empower patients
participating in early clinical studies by giving
them a way to directly contribute to drug
development on their terms. Patients are at
complete liberty to decide whether they want to
participate, what information they volunteer,
and when they do so, giving them the unique
opportunity to contribute as a partner in drug
development. In designing this approach, the
PROACT team embraced the principles of
relevant laws and regulations as part of the
solution, not the problem. They used privacy by
design and managed to balance the need to
maintain the integrity of the clinical trial
process so that the clinical trial itself remained
objective, unbiased, and uncompromised in its
scientific integrity. PROACT breaks through the
traditional pharma concept of a
‘communication gap’ between the patients in
studies and the researchers developing the drug.
As the PROACT approach is so radically
different to traditionally accepted
methodology, and shifts the information flow
from the sponsor and/or clinical teams, to the
patients who drive and choose content, testing
this system for the first time brought with it a
high level of uncertainty. Therefore, we
developed a pilot system, and conducted a
pilot study that was limited in scale so that
the utility of PROACT could be explored in the
clinical oncology setting, without inadvertently
increasing risks in other areas. Furthermore, we
conducted in parallel a patient forum meeting
to enhance our learning and implementation of
the system by gathering information on
communication needs within early clinical
trials and pulling this into the PROACT
approach. It is the learning gathered during
the pilot and the correlating patient focus group
meeting that is presented in this report.
METHODS
PROACT Design and Development
PROACT was a password-protected mobile
application developed with ease of use and
security in mind. It had a help function that
contains a video on how to use the application,
and a link to a technical support team for help
with password resets and any technical issues.
The application allowed patients to record
messages (audio/video) and for these to be
streamed to a server and made instantly
viewable to the patient’s onsite clinical team
who were then able to respond appropriately.
Patients received a return video/audio message
in a chronologically arranged ‘message list’ that
they were able to view at will.
After a delay of 32 days, the patient’s
message was sent through to a small group of
independent analysts. This delay was to ensure
that any adverse event information was
discussed between the patient and their onsite
clinical team and that all relevant updates were
entered into the clinical study database for
reporting as per the clinical study protocol.
The analysts removed personally-identifiable
information while capturing the patient
message which was then relayed to the
sponsor’s study team for further analysis (see
Fig. 1).
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Patients and medical team members had the
ability to trigger deletion of any of their own
videos recorded and uploaded to the PROACT
system by pressing the ‘delete’ button within
the application. This triggered total deletion of
that video and associated information (but not
analyzed/anonymized data).
Data Storage and Protection
Rigorous controls were implemented to ensure
data protection and patient confidentiality. All
connections to the PROACT application were
secured via https using a digital certificate.
Within the PROACT environment, encrypted
data were hosted by the Safe Harbor Certified
Provider (Rackspace) in accordance with
national and international standards on data
protection [8–10]. User access to decrypted data
was granted at different levels dependent on
role (patient, investigator, administrator,
sponsor).
Pilot Study Objectives
The pilot study was conducted using a clinical
protocol, which had been developed, written
and submitted to an Ethics Committee for
approval. The objectives were to investigate
the uptake and use of PROACT when made
available to patients undergoing treatment for
cancer in a clinical trial setting and to
characterize the information that patients
volunteered. The principal focus in this respect
was to understand the technicalities and
practicalities of the application. The study was
also designed to preliminarily assess the
potential benefit of receiving direct feedback
from patients for the sponsor, and to explore
analysis methods that would convert the
information into an interpretable dataset
while also protecting patient privacy. The
objectives were developed with the long-term
aim of PROACT being used in a way that fits
with patients’ day-to-day lives.
3) Investigator/medical 
team* view video
Patient information goes straight
through to medical team
Medical team can respond using
PROACT if they want to
1) Getting started: informed consent, app installation, tutorial
4) After a delay of 32 days, patient videos are released 
to a small, firewalled, named group of analysts
5) Analysis output
2) Patient uploads 
video
*Medical team: a small group of pre-defined medical team members that the investigator wished to have access to this 
information (eg, research nurse). Each had a secure log-in to PROACT, but all members of this team had access to the 
same account to facilitate sharing of information and collaboration between medical staff assigned to that patient. 
Fig. 1 Information ﬂow using PROACT
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Study Design, Participants, and Data
Collection
Patients aged C18 years recruited to Phase I
AstraZeneca (the sponsor) oncology studies at
the Sarah Cannon Research Institute, London,
UK were eligible to participate. Patients were
also required to have a ‘‘smart’’ phone or tablet
computer that they were willing to use (without
reimbursement) for the transmission of audio/
video recordings. Provision of informed written
consent was also required.
Following enrolment, patients downloaded
the PROACT application to their ‘‘smart’’ phone
or computer tablet and were instructed on its
technical use. Beyond technical advice, patients
were provided minimal guidance on use of the
system. This allowed the sponsor to gather
insight into the nature and level of support
that PROACT use may require in the future,
albeit from a small sample of patients already
comfortable with using mobile devices.
Patients’ messages were created, transmitted
and handled as described previously.
Data Analysis
Data evaluation focused on identifying
contextual key words and topics, using
manual text analysis of transcribed data.
Patient-identifiable data was removed while
capturing the message a patient wanted to
convey in an interpretable dataset. To enable
this, a hierarchical dictionary and flexible
coding database were created to allow for
aggregation of data, while linking back to the
patient’s own words (see Fig. 2). The database
comprised a series of entries, each comprising a
coded patient identity, date of communication,
data category (e.g., safety, efficacy,
convenience), data group (e.g., system
affected), topic (e.g., specific treatment
burden), the patient quote, status of the
communicated event/issue, and response/
outcome. Also, a simple color scale was
included to visualize the impact of the
reported topic upon that patient’s wellbeing or
daily activities [green, minimal impact on
quality of life (also used to describe if an event
had resolved or was improving); amber,
moderate impact on quality of life, able to
generally continue daily living activities with
some limitation (also used to describe an
ongoing event); red, significant impact on
quality of life (also used to describe a new or
worsening event)]. The nature and content of
the messages, therefore, drove the development
of the dictionary and coding database in an
iterative process. These outputs were then
assessed to see whether they were able to
capture the core elements of the patient
contribution in a format that would be useful
for contributing to drug programme decisions.
Ethical Approval
The study received Ethical Research Committee
approval (with positive comments regarding
steps taken to ensure patient confidentiality
and data protection) and it was conducted in
accordance with applicable regulatory
requirements and other relevant guidelines,
such as patient data privacy requirements
previously described [8–10].
Patient Forum
In parallel with the pilot study, we conducted
an interactive meeting with patient and carer
representatives of the National Cancer Research
Institute’s Consumer Forum (in the UK).
Participants in a patient focus group were
invited to provide insights into the needs of
cancer patients during treatment with a focus
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on communications in the clinical trial
environment. Open forum discussions initially
concentrated on three main areas: (1) current
clinical practice, (2) patient needs, and (3) carer
needs and contributions. The first half of the
discussion focused on people’s experiences and
opinions before the PROACT concept was
unveiled (to mitigate against any bias that
proposing PROACT may have introduced). The
second half of the session focused on discussion
and input into PROACT itself: the concept,
approach, use, and guidance. Information
gathered was used to assess whether any
improvements could be made to the use of
PROACT during the pilot study, and as well as
aiding development of an enhanced version if




Of the 16 patients informed of the PROACT
initiative (12 male, 4 female), 8 patients already
possessed and used a computer tablet or
smartphone and consented to take part.
Participating patients were marginally younger
(mean age 61 years; range 45–68 years) than
those ineligible to participate through lack of
access to mobile technology (mean age 67 years;
range 51–80 years).
Usage and Information Shared
The use of PROACT varied between individuals,
with some patients using the application many
times a week and others rarely or not at all (the
latter stated that they did not feel that they had
much or anything to share). All messages
volunteered by patients were very relevant and
informative for drug development. Topics
covered included the impact of safety and
tolerability, relay of self-monitored results
(e.g., blood pressure), feedback on study
design, and information relating to the
formulation of the medications (see Table 1).
Patient feedback on the PROACT approach itself
was also positive, highlighting the patient’s role
in drug development (e.g., ‘‘It is gratifying to
know that I have a role in the development of
the drug. To believe that this may help others in
the future is a real reward too.’’).
Patient feedback via PROACT provided an
extra level of insight. Alignment with the









Minimal impact on 
QOL
Resolved
Linked to code and quote; 
impact colour coded scale 
applied
Code: E1234AAA
Quote: “Experienced blotchy 
dry skin from Day 3 which 
didn’t affect my ability to 
function although it was 
distracting. It resolved after 
using a hydrating cream for a 
few days”
Fig. 2 Hierarchical dictionary and ﬂexible coding database; terminology tree example. QOL quality of life
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understanding of tolerability, the impact on
patients and the overall consequences (see
Table 2).
Data Analysis
The coded database was visualized in a series of
graphs to explore potential signals (Fig. 3). All
data points were supported with the patient’s
own words and these were readily accessible so
that the patient’s intended message could be
seen by the clinical team.
This ability to work with both aggregated
individual data provided efficient interpretation
and alignment of patient contributions. Thus,
the study sponsor was able to (1) spot trends,
such as the most frequently talked about topics
and the temporal emergence of topics, (2)
identify the aspects of study treatment and/or
study conduct having most impact on patients,
Table 1 Examples of patient feedback received by topic
Topic Example feedback
Safety Patient was monitoring own blood pressure and sending results
back to medical team in between visits
Example quotes include:
‘‘I spent Sunday in bed shaking off a headache and feeling unwell’’
‘‘I’m not doing an awful lot because of the fatigue that is really quite,
quite overwhelming’’
Convenience ‘‘The taste of the pills is unpleasant even though they are in the mouth
for only a couple of seconds, … If it was possible to mask the taste
of the pills that might help’’
‘‘A 12 h interval between taking the medicine which requires a 3 h fast,
2 before and 1 after, is inconvenient as say, 0700 h [morning administration]
and 1900 h [evening administration] … is not a good time in the evening to
fast if you are trying to live a normal life’’
Study design ‘‘I have been fairly tired as this is second day after chemo and the fairly
demanding day of giving blood for the trial’’
Table 2 Example comparison of clinical and PROACT data relating to the topic
Data source Information recorded/feedback provided
Clinical study database MedDRA term ‘Rash’, CTCAE Grade 1, ongoing
PROACT ‘‘The rash is gone from my face and is greatly reduced on my chest’’
‘‘It is also quite unpleasant to expose my skin to hot
water—I don’t enjoy a shower or a bath’’
‘‘My skin continues to be dry but is responding to
stuff called Bach’s rescue cream and is not a problem’’
MedDRA medical dictionary for regulatory activities, CTCAE common terminology criteria for adverse events
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(a) Minimal impact on quality of life. Also used to describe
if an event had resolved or was improving.
Moderate impact on quality of life. Patient able to 
generally continue daily activities with some limitation.
Also used to describe an ongoing event.
Significant impact on quality of life. Also used to describe
a new or worsening event.
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Fig. 3 Analysis and graphical representation of feedback
through PROACT. a Total number of quotes by topic.
b Reported impact of condition/medication on health.
c Total number of quotes over time. d Response/outcome.
OTC over-the-counter
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and (3) identify management techniques that
provide the greatest benefit for patients,
including some techniques being developed by
patients themselves.
Patient Forum Feedback
A total of five patients participated in open
discussions regarding communication in early
clinical trials and provided evaluation of the
PROACT concept. General feedback on
communication within early clinical trials
showed that there is a need for greater
communication involving patients, carers and
health care providers, with a focus on patient
experience to build empathy, provide
reassurance, ensure transparency and to
document more patient-orientated
information (see Table 3). In the following
session, patients were briefly told of the
PROACT concept and were asked to discuss its
potential features and usage (see Table 4). The
group generally agreed that the concept was
advantageous and that having a means to send
messages between site visits would provide
extra insight into the patient experience.
Patients considered that being able to send
messages ad hoc and at scheduled times to both
be beneficial, and they considered an option to
receive messages, particularly relating to study
status, a key attribute. However, they
considered that uptake and usage would
depend on ease of use, while security features
should be pitched at an appropriate level so as
to not be off putting.
DISCUSSION
This study was intended to provide feedback on
the utility of PROACT in a small cohort of
patients in early oncology clinical trials. Mobile
technology has been previously shown to
improve clinical outcomes when an interactive
application was used by patients and health care
providers outside a clinical trial [11]. However,
the PROACT interactive application is the first
to our knowledge to have been used to give
patients a way to contribute to drug
understanding on their own terms within a
clinical trial. Indeed, this pilot study
demonstrated that PROACT is a valid
approach to engage and empower patients in
early oncology clinical trials and to gain further
insight into their experience beyond that
captured in the traditional clinical data set. It
facilitated communication between patients,
the clinical team, and the sponsor, on specific
topics such as, safety, dosage administration,
and study design, while also providing added
and complementary information on
tolerability.
The development of PROACT has required
successful navigation through the complex
regulatory, ethical, and legal landscape of the
pharmaceutical industry and regulatory
environments. The outcome was a system and
process that ensured patient confidentiality and
security of data. PROACT also demonstrated that
patient communications could be captured and
interpreted in a useful format by implementing a
hierarchical dictionary and flexible coding
database. Bringing these elements together, this
small study showed that there are significant
potential benefits for patients, the clinical team,
and the sponsor. Patients receive an easy-to-use
video communication application and a way of
linking to a key ‘anchor’ person at the clinical
trial site. The onsite clinical team is able to see
and review the patients simply and quickly
between visits. As patients’ insight is also
aggregated for the overall study population,
they also receive a better understanding of drug
tolerability, thereby gaining a direct
understanding from patients across the whole
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study and in a non-clinical setting, i.e., at home.
This enables better understanding and better
patient management of tolerability issues during
an ongoing clinical study and builds a ‘patient’
knowledge base, which may be used for
subsequent related studies. Also, the sponsor
receives broad insight into the impact the drug is
having on patients that includes information
related to tolerability, formulation, convenience,
and study conduct. This enables assessment of
the recommended dose on a comprehensive
dataset generated from both the clinical report
form and direct patient feedback.
Limitations of this pilot study include the
small sample size, the iterative process that led
to the development of the coded database (no
saturation criteria were used for feedback
topics), use of an early version of the
application, and the low uptake rate due to
patients not possessing the appropriate
technology. Of note, feedback from patients
on the use of the application itself was positive,
but in spite of this, it became apparent that
patients, in general, were not aware of the value
their contribution could make. Patients
sometimes did not share insight in the pilot





Feedback reporting does not always capture the right
information (e.g., patient-reported outcomes
questionnaires)
‘‘… there was no opportunity to get any sort of personalised
data’’… ‘‘There was no emotional-type stuff, to convey how
you were feeling’’
There is a communication gap in overall health provision Although there are communication channels to the GP
(dependent on whether the site investigator approves),
A&E, and clinical study site there is still an unmet need
‘‘Clinical site: emergency 24 help number, but what if it’s not
an emergency just something that’s bothersome? GP surgery:
can’t get an appointment. A&E: only if you’re ‘dying’. There
is a need for a channel where you can communicate when
you need to and you know that the medical team will pick it




There is a need for a knowledgeable ‘‘anchor’’ person An anchor person should be available to answer questions and
provide reassurance—not at set appointments. The response
doesn’t have to be immediate but it does need to be
provided within polite/reasonable timelines
There is a need for open-ended patient feedback Patients want to tell people some things that they never get
asked. Simple things such as ‘what do you think of the shape
of the tablets’. No one ever asks, but sometimes it might be
something that is quite difﬁcult to deal with. To just be able
to tell someone who can potentially do something about it
There is a need to provide opportunities to build empathy
and to share information
Patients need to feel valued and that they are helping to ‘‘build
something’’—this can be motivational and provides a
purpose for participation. Patients also want to know what
is ‘‘going on’’
Carer needs Carers should have the opportunity to communicate too Carers can raise issues that the patient may not perceive, but
there should be separate communication channels for carers
and patients to ensure patient privacy and to provide a route
of communication back to the patient if appropriate. Carers
may also communicate on behalf of a patient where the
patient is reluctant or has inhibitions about communicating
their true experience
A&E accident and emergency, GP general practitioner
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study simply because they did not think that
anyone would want to know about it. This is a
hurdle that needs to be overcome, so that
decisions in clinical management and drug
development can be based on a broad and rich
understanding of patient experiences and
needs. Additional guidance will be developed
and made available for both patients and
medical teams in future. This will include the
points that have been learned from the pilot
study, topics of interest, the usefulness and
value of the information, and imbedding
PROACT within standard clinical study
communication channels. Additional insight





Having a way to send messages between
visits may provide extra insight
‘‘The problem we have at the moment is that the only way an
issue [such as the way you feel] is captured is when we go back
to see the doctor after 48 h, after 1 week, after 2 weeks,
whenever the next cycle is due. Which means [by that time]
(A) we’ve probably forgotten how bad we felt, (B) we’ve
probably forgotten some aspects, and (C) we may be more
focused on … getting the next dose’’
Patients may beneﬁt from ability to record
both ad hoc and scheduled messages
‘‘I can see it as a tool for contacting doctors. I think it’s brilliant.
But in terms of a tool for contributing to a trial on a regular
basis that might be hard to achieve’’
‘‘On the other hand, it could genuinely be quite helpful in itself,
but also quite motivational. We take part in trials—yes of
course we want the beneﬁt for ourselves—but the other reason
we do it is to help other people …’’
Study
updates
Study updates are considered to be key
elements of communication
Content: basic updates on study design and progress.
Recruitment? Is the drug working in anyone? Emerging side
effects? Whatever is possible, given that patients understand




Ease of use is considered integral
to uptake
User experience of technology is integral to whether people
communicate and become involved. Button to switch on/off
camera (i.e., option to record audio or video that is clearly
delineated). No strong desire for typing, if anything, the
opposite. Request for ﬁltering/search facilities. Request for
emoticons on video as optional—patients setting sentiment
that they had at the time themselves. Pop up reminders for
schedule. Notiﬁcation for delay in response
Security
features
Security features need to be appropriate
but not off-putting
Remembering pin codes can be a problem for some patients.
There is a need to consider the security of storing information
on the device versus instant streaming. Instant-stream
messaging may be inconvenient, especially if it does not work
ofﬂine
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from the patient forum will be used to develop
an enhanced version of the PROACT
application that will also be made available for
download to laptop/desktop computers. It is
intended to provide more information on the
use of the application and information relating
to the study medication together with
comprehensive management guidelines
(including practical tips from previous patient
experiences when taking the drug). In the wider
context, it is intended that PROACT be
incorporated as an element in the drug
development process, contributing to
bioinformatics and providing patients with
personalized data feedback.
CONCLUSIONS
In summary, PROACT achieved initial proof of
concept and delivered a secure end-to-end
system that protected patient privacy while
providing preliminary patient insight into
clinical trial participation. In this respect, it
appears to provide a new way of engaging and
empowering patients with the potential to
change the communication paradigm for an
ongoing clinical trial. As previous studies have
shown, engaged patients who have the skills,
ability, and willingness to help manage their
own health have better health outcomes at
lower cost to the health system [12]. Further
validation of this technology in larger patient
cohorts using an enhanced application is
ongoing.
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